Established in 2010, Crystal Pharmatech is a specialized CRO/CDMO, excelling in crystal form and formulation services. Our exceptional track record includes supporting 1,000 clients and collaborating on over 2,000 compounds, showcasing our expertise in solid-state research, crystallization, pre-formulation, formulation development, and manufacturing. With a global presence encompassing three strategically located R&D centers in Suzhou (China), New Jersey (USA), and Toronto (Canada), we are powered by a skilled team of around 250 professionals. As a leader in both conventional and enabling formulation technologies, including amorphous solid dispersion, we take pride in our cGMP facilities, strictly adhering to the rigorous standards set by the FDA, EMA, and NMPA. Our integrated service encompasses the entire new drug development journey, from developability assessment and solid form screening to pre-formulation, formulation development, and CTM and commercial manufacturing. Introducing our pioneering Mol2Med program, designed to expedite small molecule lead compounds or preclinical candidates into Phase I and beyond, with unparalleled efficiency and precision. This 3-step First-Time-Right approach begins at the lead optimization/PCC stage: Step 1: Developability Assessment to guide API form selection and formulation design. Step 2: Solid form screening/selection and Preformulation. Step 3: Formulation development and CTM manufacturing, including packaging, labeling, and shipping to the clinical site. This innovative approach guarantees a robust API form and a scalable manufacturing process, culminating in a First-Time-Right formulation for Phase I. Streamlining the transition to future clinical studies upon Phase I success, our First-Time-Right approach sets the foundation for optimized drug development and success beyond.
View Top Employees from Crystal PharmatechWebsite | http://www.crystalpharmatech.com |
Revenue | $33 million |
Funding | $10 million |
Employees | 81 (81 on RocketReach) |
Founded | 2010 |
Address | 3000 Eastpark Blvd Suite 500B, Cranbury, New Jersey 08512, US |
Phone | (609) 604-8303 |
Industry | Pharmaceutical Manufacturing, Drug Stores & Pharmacies, Drug Discovery, Salt Screening, Retail, Other Pharmaceuticals and Biotechnology, Polymorph Screening, Cocrystal Screening, API characterization, API process optimization, API crystallization, Chiral Resolution, Preformulation, Amorphous Solid Dispersion, Formulation Characterization, Crystallization Development And Optimization |
Web Rank | 7 Million |
Keywords | Crystalpharmatech, Crystal Pharma, Xrpd Crystal Pharmatech Analysis, 苏州科睿思制药有限公司, Crystal Pharmatech Inc. Usa |
Competitors | Alpha Clinical Systems, Criterium Inc., Primesoft Inc, Quality Data Services, Inc., Syreon: Celebrating 20 Years of Leading Research |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies |
Looking for a particular Crystal Pharmatech employee's phone or email?
The Crystal Pharmatech annual revenue was $33 million in 2024.
Robert Wenslow is the Vice President Business Development of Crystal Pharmatech.
81 people are employed at Crystal Pharmatech.
Crystal Pharmatech is based in Cranbury, New Jersey.
The NAICS codes for Crystal Pharmatech are [3254, 325, 32, 32541].
The SIC codes for Crystal Pharmatech are [283, 28].